Lv4
800 积分 2025-12-03 加入
SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial
2个月前
已完结
A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density
2个月前
已完结
Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study
2个月前
已完结
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
2个月前
已完结
Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study
2个月前
已完结
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
2个月前
已完结
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
2个月前
已完结
Romosozumab in postmenopausal women with low bone mineral density
2个月前
已完结
Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial
2个月前
已完结
Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12
2个月前
已完结
皖公网安备34019202002308
